News: Protagonist is pleased to announce the submission of a New Drug Application for icotrokinra, the first- and best-in-class oral IL-23R blocker for plaque #psoriasis. Four pivotal Phase 3 ICONIC studies back its potential to transform care and expand across IL-23–mediated

At Protagonist, our highly specialized team of technical experts have developed a proprietary technology platform that has led to numerous highly unique recipes in the field of peptide therapeutics. Learn about our approach to new peptide discoveries:

Happy 4th of July to our U.S.-based friends and colleagues! 🎆. Today, we celebrate the spirit of independence and the ongoing pursuit of progress, both in our nation and in the work we do to advance peptide-based therapeutics. We wish everyone a restful and memorable

Today, we hosted a conference call and webcast on our oral obesity development candidate, PN-477. IND-enabling studies are underway, with Phase I study initiation expected in the second quarter of 2026. Read more: Watch the webcast replay:

Join us today at 4:30pm ET as we host a conference call and webcast to announce our oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Access the webcast here:

On June 30th at 4:30pm ET, we will host a conference call to announce our oral obesity development candidate and share in vitro and pre-clinical proof-of-concept study results. Access the webcast link here:

Earlier this month, @MoffittNews Cancer Center's Dr. Andrew @KuykendallMd delivered an engaging presentation on the latest results from the phase 3 VERIFY study in polycythemia vera (PV) during #ASCO25's Plenary Session. ICYMI, see the abstract here:

Dr. @AaronGerds from the @ClevelandClinic spoke with @cure_today about iron deficiency challenges faced by polycythemia vera (PV) patients as a result of frequent phlebotomies and how an investigational hepcidin mimetic works to control red blood cell production. Watch the full.

Our Protagonist team is excited to be in Milan, Italy to kick off #EHA2025!. We look forward to an inspiring meeting as the world's top hematologists gather to share the latest research in hematology and patient care.

RT @ProtagonistCEO: Great coverage of rusfertide in today’s @WSJ. Developing rusfertide has been a long, passionate journey for @Protagoni….

What a week for Protagonist! From the #ASCO2025 plenary spotlight on rusfertide to our investor call and #JefferiesHealthcare appearance, it’s a testament to progress and momentum ahead. Grateful to our team, partners, investigators & patients.

Great to be back at the @Jefferies Healthcare Conference. @ProtagonistCEO Dinesh V. Patel shared why our rusfertide data was called “practice-changing” by independent experts at #ASCO25, as well as what’s next for our IL-23/IL-17 programs and capital strategy. Watch the replay:

This Wednesday at 1:25PM ET, our @ProtagonistCEO Dinesh V. Patel, PhD, will participate in a fireside chat and one-on-one meetings at #JefferiesHealthcare. Access the webcast:

After the plenary presentation yesterday at #ASCO25, @ProtagonistCEO Dinesh V. Patel, PhD, had a great conversation with @bradloncar on @BiotechTV about the latest rusfertide data and what's next for Protagonist.

Thank you to Dr. Andrew @KuykendallMd from Moffitt Cancer Center (@MoffittNews) for presenting results from the Phase 3 VERIFY study at this year's Plenary Session. (2/2)

This past weekend, the world's top oncologists gathered in Chicago to share the latest research in cancer care for the 2025 @ASCO Annual Meeting. We appreciate everyone who joined us and helped make #ASCO25 a success! (1/2)

RT @MoffittNews: Live from #ASCO25: Andrew Kuykendall, MD, (@KuykendallMd) joins us to share the practice changing results from the VERIFY….

RT @MoffittNews: Live from #ASCO25: Moffitt’s Andrew Kuykendall, MD, (@KuykendallMd) presents practice changing results from the VERIFY stu….

Results from the Phase 3 VERIFY trial of rusfertide are being featured in today's #ASCO25 Plenary Session, presented by Dr. Andrew T. @KuykendallMd of Moffitt Cancer Center (@MoffittNews). @ASCO’s selection of the VERIFY trial for plenary presentation is an important milestone

Join us this Sunday, June 1st at 2:09PM CDT as Dr. Andrew Kuykendall (@KuykendallMd) from Moffitt Cancer Center presents an abstract featuring results from the VERIFY Phase 3 study in patients with polycythemia vera (PV) during the Plenary Session at #ASCO25. More details here: